Cellectar Biosciences Announces AACR Oral Presentation for Pediatric Cancer Treatment

Cellectar Biosciences announced that an abstract for an oral presentation and panel discussion on interim data from its Phase 1b study of iopofosine I 131 in relapsed or refractory pediatric high-grade glioma has been accepted at the American Association for Cancer Research Special Conference on Pediatric Cancer. The presentation will highlight the treatment of pediatric high-grade glioma patients with the drug.

Cellectar Biosciences (NASDAQ: CLRB) has announced that an abstract for an oral presentation and panel discussion on interim data from its Phase 1b study of iopofosine I 131 in relapsed or refractory pediatric high-grade glioma has been accepted at the American Association for Cancer Research (AACR) Special Conference on Pediatric Cancer. The presentation, scheduled for September 26, 2025, will highlight the treatment of pediatric high-grade glioma patients with iopofosine I 131.

The oral presentation will be followed by a 55-minute panel discussion, allowing for further exploration of the interim data from the CLOVER-2 Phase 1b clinical trial. The study is evaluating the safety and tolerability of iopofosine I 131 in two dosing cohorts, with the aim of determining the recommended Phase 2/3 dose for children, adolescents, and young adults with relapsed or refractory pediatric high-grade glioma (r/r pHGG).

The interim data, presented by Chief Operating Officer Jarrod Longcor, is expected to provide insights into the clinical potential of iopofosine I 131 for treating aggressive cancers in patients with limited treatment options. The study is ongoing and involves patients diagnosed with various types of high-grade gliomas, including diffuse midline gliomas (DMG), ependymomas, diffuse intrinsic pontine gliomas (DIPG), diffuse hemispheric gliomas (DHG), and anaplastic ependymomas.

The median progression-free survival (PFS) and overall survival (OS) for patients with relapsed pHGG are reported to be poor, with approximately 2.25 months and 5.6 months, respectively. While MRI measures of tumor volume change can be helpful, they often fail to predict survival.

Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer. The company's core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments.

References:
[1] https://www.stocktitan.net/news/CLRB/cellectar-biosciences-to-present-data-in-oral-session-and-panel-iwj3zvs3iumz.html
[2] https://www.globenewswire.com/news-release/2025/08/27/3139982/29076/en/Cellectar-Biosciences-to-Present-Data-in-Oral-Session-and-Panel-Discussions-at-the-American-Association-for-Cancer-Research-Special-Conference-on-Discovery-and-Innovation-in-Pediat.html